Drug intelligence / Profile preview

BI 498306

Development stage: Preclinical
Lead developer: Boehringer Ingelheim
Modality: Small Molecules

Overview

BI 498306 is an experimental chemical compound developed by Boehringer Ingelheim for potential therapeutic use, specifically being investigated as a treatment for schizophrenia. Due to its early-stage and investigational status, detailed information about its mechanism of action, pharmacology, and clinical data remains limited. As of now, the precise molecular target or pathway modulated by BI 498306 has not been disclosed publicly[1][2].

Beyond the preview

Go deeper on BI 498306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 498306.

Explore the full profile